Literature DB >> 33426569

Non-alcoholic Fatty Liver and Liver Fibrosis Predictive Analytics: Risk Prediction and Machine Learning Techniques for Improved Preventive Medicine.

Orit Goldman1, Ofir Ben-Assuli2, Ori Rogowski3, David Zeltser3, Itzhak Shapira3, Shlomo Berliner3, Shira Zelber-Sagi4,5, Shani Shenhar-Tsarfaty3.   

Abstract

Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease worldwide, with a prevalence of 20%-30% in the general population. NAFLD is associated with increased risk of cardiovascular disease and may progress to cirrhosis with time. The purpose of this study was to predict the risks associated with NAFLD and advanced fibrosis on the Fatty Liver Index (FLI) and the 'NAFLD fibrosis 4' calculator (FIB-4), to enable physicians to make more optimal preventive medical decisions. A prospective cohort of apparently healthy volunteers from the Tel Aviv Medical Center Inflammation Survey (TAMCIS), admitted for their routine annual health check-up. Data from the TAMCIS database were subjected to machine learning classification models to predict individual risk after extensive data preparation that included the computation of independent variables over several time points. After incorporating the time covariates and other key variables, this technique outperformed the predictive power of current popular methods (an improvement in AUC above 0.82). New powerful factors were identified during the predictive process. The findings can be used for risk stratification and in planning future preventive strategies based on lifestyle modifications and medical treatment to reduce the disease burden. Interventions to prevent chronic disease can substantially reduce medical complications and the costs of the disease. The findings highlight the value of predictive analytic tools in health care environments. NAFLD constitutes a growing burden on the health system; thus, identification of the factors related to its incidence can make a strong contribution to preventive medicine.

Entities:  

Keywords:  Machine learning; Non-alcoholic fatty liver disease; Predictive analytics; Risk prediction

Mesh:

Year:  2021        PMID: 33426569     DOI: 10.1007/s10916-020-01693-5

Source DB:  PubMed          Journal:  J Med Syst        ISSN: 0148-5598            Impact factor:   4.460


  14 in total

Review 1.  Causes and metabolic consequences of Fatty liver.

Authors:  Norbert Stefan; Konstantinos Kantartzis; Hans-Ulrich Häring
Journal:  Endocr Rev       Date:  2008-08-21       Impact factor: 19.871

Review 2.  The global NAFLD epidemic.

Authors:  Rohit Loomba; Arun J Sanyal
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-09-17       Impact factor: 46.802

Review 3.  The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases.

Authors:  Naga Chalasani; Zobair Younossi; Joel E Lavine; Michael Charlton; Kenneth Cusi; Mary Rinella; Stephen A Harrison; Elizabeth M Brunt; Arun J Sanyal
Journal:  Hepatology       Date:  2017-09-29       Impact factor: 17.425

4.  The Fatty Liver Index (FLI) Relates to Diabetes-Specific Parameters and an Adverse Lipid Profile in a Cohort of Nondiabetic, Dyslipidemic Patients.

Authors:  Michael Leutner; Christian Göbl; Oliver Schlager; Silvia Charwat-Resl; Alice Wielandner; Eleonora Howorka; Marlies Prünner; Latife Bozkurt; Katharina Maruszczak; Hacer Geyik; Helmut Prosch; Giovanni Pacini; Alexandra Kautzky-Willer
Journal:  J Am Coll Nutr       Date:  2017-05-16       Impact factor: 3.169

5.  Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD.

Authors:  Hannes Hagström; Patrik Nasr; Mattias Ekstedt; Ulf Hammar; Per Stål; Rolf Hultcrantz; Stergios Kechagias
Journal:  J Hepatol       Date:  2017-08-10       Impact factor: 25.083

6.  Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up.

Authors:  Mattias Ekstedt; Hannes Hagström; Patrik Nasr; Mats Fredrikson; Per Stål; Stergios Kechagias; Rolf Hultcrantz
Journal:  Hepatology       Date:  2015-03-23       Impact factor: 17.425

7.  Prevalence of primary non-alcoholic fatty liver disease in a population-based study and its association with biochemical and anthropometric measures.

Authors:  Shira Zelber-Sagi; Dorit Nitzan-Kaluski; Zamir Halpern; Ran Oren
Journal:  Liver Int       Date:  2006-09       Impact factor: 5.828

8.  Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials.

Authors:  Quentin M Anstee; Eric J Lawitz; Naim Alkhouri; Vincent Wai-Sun Wong; Manuel Romero-Gomez; Takeshi Okanoue; Michael Trauner; Kathryn Kersey; Georgia Li; Ling Han; Catherine Jia; Lulu Wang; Guang Chen; G Mani Subramanian; Robert P Myers; C Stephen Djedjos; Anita Kohli; Natalie Bzowej; Ziad Younes; Shiv Sarin; Mitchell L Shiffman; Stephen A Harrison; Nezam H Afdhal; Zachary Goodman; Zobair M Younossi
Journal:  Hepatology       Date:  2019-08-19       Impact factor: 17.425

9.  The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis.

Authors:  Thierry Poynard; Vlad Ratziu; Sylvie Naveau; Dominique Thabut; Frederic Charlotte; Djamila Messous; Dominique Capron; Annie Abella; Julien Massard; Yen Ngo; Mona Munteanu; Anne Mercadier; Michael Manns; Janice Albrecht
Journal:  Comp Hepatol       Date:  2005-12-23

10.  Fatty liver index is a strong predictor of changes in glycemic status in people with prediabetes: The IT-DIAB study.

Authors:  Matthieu Wargny; Sarra Smati; Matthieu Pichelin; Edith Bigot-Corbel; Charlotte Authier; Violette Dierry; Yassine Zaïr; Vincent Jacquin; Samy Hadjadj; Jérôme Boursier; Bertrand Cariou
Journal:  PLoS One       Date:  2019-08-29       Impact factor: 3.240

View more
  3 in total

Review 1.  Perspectives on Precision Medicine Approaches to NAFLD Diagnosis and Management.

Authors:  Amedeo Lonardo; Juan Pablo Arab; Marco Arrese
Journal:  Adv Ther       Date:  2021-04-07       Impact factor: 3.845

2.  Machine learning using longitudinal prescription and medical claims for the detection of non-alcoholic steatohepatitis (NASH).

Authors:  Ozge Yasar; Patrick Long; Brett Harder; Hanna Marshall; Sanjay Bhasin; Suyin Lee; Mark Delegge; Stephanie Roy; Orla Doyle; Nadea Leavitt; John Rigg
Journal:  BMJ Health Care Inform       Date:  2022-03

3.  A Noninvasive Risk Stratification Tool Build Using an Artificial Intelligence Approach for Colorectal Polyps Based on Annual Checkup Data.

Authors:  Chieh Lee; Tsung-Hsing Lin; Chen-Ju Lin; Chang-Fu Kuo; Betty Chien-Jung Pai; Hao-Tsai Cheng; Cheng-Chou Lai; Tsung-Hsing Chen
Journal:  Healthcare (Basel)       Date:  2022-01-17
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.